ST-Segment Elevation Infarction After TAVR: Problems in Every Aspect

For interventional cardiologists, treating an ST-segment elevation infarction in a patient with transcatheter aortic valve replacement (TAVR) is challenging in many ways. Longer door-to-balloon times and higher rates of primary angioplasty failure than in the general population are translated into very high short- and mid-term mortality.

Infarto con supradesnivel del ST post TAVI: problemas en todos los sentidos

This multicenter study, recently published in JACC, included 118 patients admitted with ST-segment elevation infarction at a mean of 225 days (range: 9 to 680 days) after valvular implantation.

The characteristics of post-TAVR infarction patients who underwent primary angioplasty were compared with 439 patients without prior TAVR who underwent primary angioplasty in the same time period.

The mean door-to-balloon time was higher for TAVR patients (40 minutes vs. 30 minutes [p = 0.003]). Procedure time, fluoroscopy time, radiation dose, and contrast volume were significantly higher for the TAVR population (p < 0.01 for all).

The primary angioplasty failure rate was 4x higher in those with implanted valves (16.5% vs. 3.9%; p < 0.001), including 5 patients whose culprit artery could not be catheterized.

In-hospital mortality was 25.4%, while mid-term mortality (7 months) was as high as 42.4%.

Renal impairment and Killip class >II were 3x more frequent in patients with previous TAVR (hazard ratio [HR]: 3.02; p = 0.004; and HR: 2.74; p = 0.004, respectively).


Read also: New Cardiac Failure Diagnoses after COVID-19 Infection.


All these more frequent events in the TAVR population explain the higher short- and mid-term mortality.

Conclusion

ST-segment elevation infarctions in patients with prior TAVR are associated with much higher short- and mid-term mortality. Longer door-to-balloon times and higher primary angioplasty failure rates are due, partly, to difficulties accessing coronary arteries.

Original Title: ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement.

Reference: Laurent Faroux et al. J Am Coll Cardiol. 2021 May 4;77(17):2187-2199. doi: 10.1016/j.jacc.2021.03.014.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...